New Drug Combo Doubles Survival Time for Pancreatic Cancer

Patients with advanced pancreatic cancer just got their best news in years. A new drug combination nearly doubled how long they lived without their disease getting worse.

The Lap-NET1 trial tested adding an antibody called NP137 to standard chemotherapy in 43 patients with locally advanced pancreatic cancer. These patients have tumors wrapped around blood vessels, making surgery nearly impossible.

The results exceeded expectations. Patients lived a median of 10.85 months without their cancer progressing, compared to the typical 6 to 10 months with chemotherapy alone. Overall survival reached 16.43 months, and 21 patients were still alive when researchers analyzed the data.

Even more remarkable, 23% of patients who started with inoperable tumors were able to have surgery after treatment. That's a huge win for a cancer where surgical removal offers the best chance of long-term survival.

The drug works by blocking netrin1, a protein that helps tumors become resistant to chemotherapy. When cancer cells undergo a process called epithelial-to-mesenchymal transition (EMT), they transform into more aggressive forms that chemotherapy can't kill effectively. NP137 prevents this transformation, keeping tumors vulnerable to treatment.

The Bright Side

This approach represents a completely new strategy for fighting pancreatic cancer. Instead of just trying to kill cancer cells harder, it removes their protective shield first.

The treatment was also well tolerated, meaning patients didn't experience severe side effects beyond what chemotherapy normally causes. That matters enormously for quality of life during treatment.

Researchers found the drug worked best in patients whose tumors had high levels of a protein called neogenin. These patients lived 15.65 months without progression, compared to 10.22 months for those with lower levels. This means doctors may eventually be able to predict who will benefit most.

Pancreatic cancer remains one of the deadliest cancers, with a five-year survival rate below 5%. It ranks as the fourth leading cause of cancer deaths worldwide. Current treatments haven't changed those odds much, making any improvement significant.

The trial was conducted across nine medical centers between March 2023 and June 2024. Patients received the drug combination every two weeks for up to 12 cycles.

Why This Inspires

For decades, pancreatic cancer has been one of medicine's toughest challenges. This trial shows that understanding the biology of how tumors resist treatment can lead to smarter solutions.

These results are still early, and longer studies with more patients will be needed. But for families facing this devastating diagnosis, hope just got a lot more tangible.